Skip to content

UltraClear AS-BK-00055Recalls & reported problems

Acclaro Corporation · Fractional Mid IR Fiber Laser System (Black) · Class 2

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00850039149023), received between Feb 19, 2026 and Feb 19, 2026 — classified as 1 injury.

The most frequently reported specific device problem is “Improper or Incorrect Procedure or Method” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 1 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Improper or Incorrect Procedure or Method1

Patient problems

  • Skin Infection1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryFeb 19, 2026Improper or Incorrect Procedure or Method

    PATIENT WAS REPORTED AS HAVING LESIONS ON FACE THAT DEVELOPED AFTER ULTRACLEAR TREATMENT. PHOTOGRAPHS PROVIDED OF THE FIRST 11 DAYS POST TREATMENT SHOWED REDNESS AND CRUSTING THROUGH THE FIRST 5 DAYS DEVELOPING INTO OPEN LESIONS BY DAY 11. THE TREATING PHYSICIAN PRESCRIBED HYPOCHLOROUS ACID SPRAY ON DAY 5 TO REDUCE REDNESS AND INFLAMMATION. ON DAY 9 THE PATIENT WAS PRESCRIBED KEFLEX (CEPHALEXIN, AN ANTIBIOTIC) AS BACTERIAL INFECTION WAS SUSPECTED. MEMBERS OF ACCLARO'S MEDICAL ADVISORY BOARD (MAB) REVIEWED THE PROVIDED PHOTOGRAPHS. THE MAB STATED THAT HAD THESE SYMPTOMS PRESENTED IN CLINIC THEY WOULD HAVE PRESCRIBED 1000MG OF VALTREX 3X PER DAY AND CULTURE THE LESIONS AS SOON AS AN OUTBREAK OCCURRED. MAB STATED THEY WOULD PRESCRIBE KEFLEX OR A SIMILAR ANTIBIOTIC AND IF THE CULTURE RESULTS INDICATED MRSA, THEY WOULD PRESCRIBE DOXYCYCLINE OR TETRACYCLINE. THIS INFORMATION WAS COMMUNICATED WITH THE REPORTING CLINIC. THE CLINIC STATED THEY DID NOT PRESCRIBE VALTREX AS THERE WAS NO HISTORY OF HERPES IN THE PATIENT, SO THEY PRESCRIBED KEFLEX. THE CLINIC CULTURED THE LESIONS AND THE RESULTS INDICATED MRSA. THE PATIENT WAS THEN PRESCRIBED VALTREX AND TETRACYCLINE. IT IS THE OPINION OF ACCLA

    Patient problems: Skin Infection

    MAUDE report 24388419 ↗

Other Powered Laser Surgical Instrument devices

All Powered Laser Surgical Instrument devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page